CUSIP 589492107SPON ADSMREOQ4 2025
77 filings · latest Feb 17, 2026
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Rubric Capital Management LP | 15.31M | $6.38M |
| 2 | 683 Capital Management, LLC | 15.03M | $6.26M |
| 3 | Ecor1 Capital, LLC | 7.86M | $3.27M |
| 4 | Schonfeld Strategic Advisors LLC | 6.09M | $2.54M |
| 5 | Tejara Capital Ltd | 2.16M | $899.9K |
| 6 | Logos Global Management LP | 1.85M | $770.9K |
| 7 | Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 1.76M | $735.4K |
| 8 | Monaco Asset Management Sam | 1.59M | $660.6K |
| 4 | Jan 9, 2026 | Ecor1 Capital, LLC | 13G | 9.4% | — | SEC |
| 5 | Jan 6, 2026 | 683 Capital Management, LLC | 13G | 8.2% | 65.08M | SEC |
| 6 | Nov 14, 2025 | Janus Henderson Group PLC | 13G/A | 10.2% | 16.29M | SEC |
| 7 | Nov 14, 2025 | Mangrove Partners Im, LLC | 13G/A | 4.9% | 389.53T | SEC |
| 8 | Aug 14, 2025 | Frazier Life Sciences Public Fund, L.P. | 13G/A | 4.1% | 32.43M | SEC |
| 9 | Aug 14, 2025 | Janus Henderson Group PLC | 13G/A | 11.1% | 17.69M | SEC |
| 10 | Jun 11, 2025 | Northpond Ventures, LP | 13G | 6.9% | 54.52M | SEC |
See the full Schedule 13D/13G history for Mereo Biopharma Group PLC.
Unlock full history| 9 |
| Ubs Group AG |
| 1.56M |
| $650.1K |
| 10 | Balyasny Asset Management L.P. | 1.28M | $533.5K |